OmniAb Inc. (OABI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
OmniAb Inc. stock (OABI) is currently trading at $1.67. OmniAb Inc. PS ratio (Price-to-Sales) is 13.65. Analyst consensus price target for OABI is $7.33. WallStSmart rates OABI as Sell.
- OABI PE ratio analysis and historical PE chart
- OABI PS ratio (Price-to-Sales) history and trend
- OABI intrinsic value — DCF, Graham Number, EPV models
- OABI stock price prediction 2025 2026 2027 2028 2029 2030
- OABI fair value vs current price
- OABI insider transactions and insider buying
- Is OABI undervalued or overvalued?
- OmniAb Inc. financial analysis — revenue, earnings, cash flow
- OABI Piotroski F-Score and Altman Z-Score
- OABI analyst price target and Smart Rating
OmniAb Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
OmniAb Inc. (OABI) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
OmniAb Inc. (OABI) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
52.12% held by institutions, strong professional interest
Supporting Valuation Data
OmniAb Inc. (OABI) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -22.50%, a shrinking business
Very expensive at 13.7x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
OmniAb Inc. (OABI) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (0.95) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (13.65) suggest expensive pricing. Growth concerns include Revenue Growth at -22.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -23.40%, Operating Margin at -147.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -23.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -22.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
OABI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
OABI's Price-to-Sales ratio of 13.65x sits near its historical average of 13.58x (29th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 10% below its historical high of 15.16x set in Mar 2026, and 16% above its historical low of 11.74x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~11.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for OmniAb Inc. (OABI) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
OmniAb Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 19M with 23% decline year-over-year.
Key Findings
Debt-to-equity ratio of 0.08 indicates a conservative balance sheet with 29M in cash.
Spending 75% of revenue (14M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 23% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact OmniAb Inc..
Bottom Line
OmniAb Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 11:50:08 AM
About OmniAb Inc.(OABI)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
OmniAb Inc. is an innovative biotechnology company specializing in the development of fully human therapeutic antibodies through its proprietary OmniAb platform. This advanced technology enables the efficient discovery and optimization of high-quality therapeutics aimed at addressing a wide array of diseases. With a strategic emphasis on collaborations and partnerships, OmniAb is committed to accelerating drug development processes and enhancing the availability of breakthrough treatments. Led by a skilled management team and supported by a robust pipeline, the company is poised to capitalize on the growing opportunities within the biopharmaceutical sector.